O	0	11	Differences
O	12	19	between
B-intervention	20	28	palpable
O	29	32	and
B-control	33	44	nonpalpable
I-control	45	51	tumors
O	52	54	in
B-eligibility	55	60	early
I-eligibility	60	61	-
I-eligibility	61	66	stage
I-eligibility	66	67	,
I-eligibility	68	75	hormone
I-eligibility	76	84	receptor
I-eligibility	84	85	-
I-eligibility	85	93	positive
I-eligibility	94	100	breast
I-eligibility	101	107	cancer
O	107	108	.

O	109	111	We
O	112	120	compared
O	121	136	characteristics
O	137	140	and
O	141	149	outcomes
O	150	152	of
O	153	161	palpable
O	162	168	versus
O	169	180	nonpalpable
O	180	181	,
O	182	189	hormone
O	189	190	-
O	190	199	sensitive
O	199	200	,
O	201	206	early
O	206	207	-
O	207	212	stage
O	213	219	breast
O	220	227	cancers
O	227	228	.

O	229	237	Patients
O	238	242	from
O	243	246	the
B-location	247	252	North
I-location	253	261	American
O	262	270	Fareston
O	271	273	vs
O	273	274	.
O	275	284	Tamoxifen
O	285	293	Adjuvant
O	294	295	(
O	295	300	NAFTA
O	300	301	)
O	302	307	trial
O	308	312	were
O	313	320	divided
O	321	325	into
O	326	334	palpable
O	335	336	(
O	336	337	n
O	338	339	=
B-intervention-participants	340	343	513
O	343	344	)
O	345	348	and
O	349	360	nonpalpable
O	361	362	(
O	362	363	n
O	364	365	=
B-control-participants	366	370	1063
O	370	371	)
O	372	377	tumor
O	378	384	groups
O	384	385	.

O	386	397	Differences
O	398	400	in
O	401	413	pathological
O	414	422	features
O	422	423	,
O	424	428	loco
O	428	429	-
O	429	437	regional
O	438	445	therapy
O	445	446	,
O	447	454	disease
O	454	455	-
O	455	459	free
O	460	468	survival
O	469	470	(
O	470	473	DFS
O	473	474	)
O	475	478	and
O	479	486	overall
O	487	495	survival
O	496	497	(
O	497	499	OS
O	499	500	)
O	501	505	were
O	506	514	analyzed
O	514	515	.

O	516	524	Patients
O	525	529	with
O	530	538	palpable
O	539	545	tumors
O	546	550	were
O	551	556	older
O	556	557	,
O	558	561	had
O	562	568	larger
O	569	575	tumors
O	575	576	,
O	577	580	and
O	581	587	higher
O	588	593	rates
O	594	596	of
O	597	602	lymph
O	602	603	-
O	603	607	node
O	608	619	involvement
O	619	620	.

O	621	624	The
O	625	631	tumors
O	632	636	were
O	637	641	more
O	642	648	likely
O	649	651	to
O	652	654	be
O	655	661	poorly
O	662	676	differentiated
O	676	677	,
O	678	680	of
O	681	685	high
O	686	693	nuclear
O	694	699	grade
O	699	700	,
O	701	704	and
O	705	712	display
O	713	727	lymphovascular
O	728	736	invasion
O	736	737	.

O	738	743	After
O	744	748	mean
O	749	757	followup
O	758	760	of
O	761	763	59
O	764	770	months
O	770	771	,
B-outcome	772	775	DFS
O	776	779	and
B-outcome	780	782	OS
O	783	787	were
O	788	801	significantly
O	802	807	lower
O	808	811	for
O	812	820	palpable
O	821	825	than
O	826	837	nonpalpable
O	838	844	tumors
O	845	846	(
B-outcome	846	849	DFS
B-iv-bin-percent	850	852	93
I-iv-bin-percent	852	853	.
I-iv-bin-percent	853	854	5
I-iv-bin-percent	854	855	%
O	856	858	vs
O	858	859	.
B-cv-bin-percent	860	862	98
I-cv-bin-percent	862	863	.
I-cv-bin-percent	863	864	4
I-cv-bin-percent	864	865	%
O	865	866	,
O	867	868	p
O	869	870	<
O	871	872	0
O	872	873	.
O	873	876	001
O	876	877	,
B-outcome	878	880	OS
B-iv-bin-percent	881	883	88
I-iv-bin-percent	883	884	.
I-iv-bin-percent	884	885	5
I-iv-bin-percent	885	886	%
O	887	889	vs
O	889	890	.
B-cv-bin-percent	891	893	95
I-cv-bin-percent	893	894	.
I-cv-bin-percent	894	895	6
I-cv-bin-percent	895	896	%
O	896	897	,
O	898	899	p
O	900	901	<
O	902	903	0
O	903	904	.
O	904	907	001
O	907	908	)
O	908	909	.

O	910	921	Controlling
O	922	925	for
O	926	929	age
O	929	930	,
O	931	935	size
O	936	939	and
O	940	945	nodal
O	946	952	status
O	952	953	,
O	954	965	palpability
O	966	969	was
O	970	972	an
O	973	984	independent
O	985	991	factor
O	992	995	for
O	996	999	DFS
O	1000	1001	(
O	1001	1003	OR
O	1004	1005	=
O	1006	1007	2
O	1007	1008	.
O	1008	1010	56
O	1010	1011	;
O	1012	1014	95
O	1014	1015	%
O	1015	1017	CI
O	1017	1018	,
O	1019	1020	1
O	1020	1021	.
O	1021	1023	37
O	1023	1024	-
O	1024	1025	4
O	1025	1026	.
O	1026	1028	79
O	1028	1029	,
O	1030	1031	p
O	1032	1033	=
O	1034	1035	0
O	1035	1036	.
O	1036	1039	003
O	1039	1040	)
O	1041	1044	and
O	1045	1047	OS
O	1048	1049	(
O	1049	1051	OR
O	1052	1053	=
O	1054	1055	2
O	1055	1056	.
O	1056	1058	12
O	1058	1059	;
O	1060	1062	95
O	1062	1063	%
O	1063	1065	CI
O	1065	1066	,
O	1067	1068	1
O	1068	1069	.
O	1069	1071	38
O	1071	1072	-
O	1072	1073	3
O	1073	1074	.
O	1074	1076	28
O	1076	1077	,
O	1078	1079	p
O	1080	1081	<
O	1082	1083	0
O	1083	1084	.
O	1084	1087	001
O	1087	1088	)
O	1088	1089	.

O	1090	1092	In
O	1093	1094	a
O	1095	1100	group
O	1101	1103	of
O	1104	1111	hormone
O	1111	1112	-
O	1112	1121	sensitive
O	1121	1122	,
O	1123	1129	mostly
O	1130	1144	postmenopausal
O	1145	1150	early
O	1150	1151	-
O	1151	1156	stage
O	1157	1163	breast
O	1164	1170	cancer
O	1171	1179	patients
O	1179	1180	,
O	1181	1189	palpable
O	1190	1196	tumors
O	1197	1201	were
O	1202	1206	more
O	1207	1213	likely
O	1214	1216	to
O	1217	1221	have
O	1222	1226	more
O	1227	1237	aggressive
O	1238	1246	features
O	1247	1250	and
O	1251	1261	metastatic
O	1262	1271	potential
O	1271	1272	,
O	1273	1278	which
O	1279	1289	translated
O	1290	1292	in
O	1293	1295	to
O	1296	1297	a
O	1298	1304	higher
O	1305	1314	incidence
O	1315	1317	of
O	1318	1324	breast
O	1325	1331	cancer
O	1331	1332	-
O	1332	1339	related
O	1340	1346	events
O	1347	1350	and
O	1351	1356	worse
O	1357	1364	overall
O	1365	1373	survival
O	1373	1374	.
